|
KMID : 1137020230340040044
|
|
Journal of Gynecologic Oncology
2023 Volume.34 No. 4 p.44 ~ p.44
|
|
|
Effectiveness and safety of nab-paclitaxel and platinum as first-line chemotherapy for ovarian cancer: a retrospective study
|
|
Liangliang Wang
Shuangying Li
Da Zhu
Yu Qin
Xiaoli Wang
Zhenya Hong
Zhiqiang Han
|
|
|
Abstract
|
|
|
Objective: To evaluate the effectiveness and safety of nab-paclitaxel plus platinum as first-line chemotherapy for ovarian cancer (OC).
Methods: Patients administered platinum combined with nab-paclitaxel as first-line chemotherapy for epithelial OC, fallopian tube cancer, or primary peritoneal cancer from July 2018 to December 2021 were retrospectively evaluated. The primary outcome was progression-free survival (PFS). Adverse events (AEs) were examined. Subgroup analysis was performed.
Results: Seventy-two patients (median age, 54.5 years; range, 20.0?79.0 years) were evaluated, including 12 and 60 administered neoadjuvant therapy and primary surgery with subsequent chemotherapy, respectively. The median follow-up duration was 25.6 months, and the median PFS was 26.7 (95% confidence interval [CI]=24.0?29.3) months in the whole patient population. In the neoadjuvant subgroup, the median PFS was 26.7 (95% CI=22.9?30.5) months vs. 30.1 (95% CI=23.1?37.1) months in the primary surgery subgroup. Twenty-seven patients were administered nab-paclitaxel plus carboplatin and had a median PFS of 30.3 (95% CI=not available [NA]?NA) months. The commonest grade 3?4 AEs included anemia (15.3%), white blood cell decreased (11.1%), and neutrophil count decreased (20.8%). No drug-related hypersensitivity reactions occurred.
Conclusion: Nab-paclitaxel plus platinum as first-line treatment in OC was associated with a favorable prognosis and was tolerable in patients with OC.
|
|
|
KEYWORD
|
|
|
Ovarian Cancer, Chemotherapy, Nab-paclitaxel
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
    
|